急性冠脉综合征患者PCI术后比伐卢定全量或低剂量输注研究
基于MATRIX研究3,610例接受比伐卢定的ACS患者,比较PCI术后是否输注比伐卢定及全量(1.75 mg/kg/h ≤4 h)与低剂量(0.25 mg/kg/h ≤6 h)方案。术后输注与否主要终点无差异,但全量方案较未输注、低剂量或肝素组与结局改善相关。
要点
- ACS患者PCI术后是否输注比伐卢定,30天主要复合终点无差异。
- 全量术后比伐卢定较低剂量方案与主要终点显著降低相关(多因素校正率比0.21)。
- 全量方案在STEMI与NSTE-ACS中与未输注或肝素组相比结局改善一致。
核心结论
- 在伴或不伴ST段抬高的ACS患者中,PCI术后比伐卢定输注与否主要终点无差异,但全量术后输注较未输注、低剂量或肝素与结局改善相关。
研究设计与样本
- MATRIX研究为随机对照研究,3,610例ACS患者分配至比伐卢定,其中1,799例随机接受、1,811例不接受PCI术后比伐卢定输注。
- 术后全量方案为1.75 mg/kg/h ≤4 h,低剂量方案为0.25 mg/kg/h ≤6 h,由术者决定;全量组612例(STEMI 399例、NSTE-ACS 213例),低剂量组1,068例(STEMI 519例、NSTE-ACS 549例)。
- 主要终点为30天紧急靶血管血运重建、明确支架血栓或净不良临床事件(全因死亡、心肌梗死、卒中或大出血的复合)的复合终点。
主要发现
- 接受与未接受PCI术后比伐卢定的STEMI或NSTE-ACS患者主要终点无差异。
- 全量较低剂量方案在多因素校正后与主要终点显著降低相关(率比0.21;95%CI 0.12–0.35;p<0.001)。
- 全量较低剂量方案在倾向评分校正后同样与主要终点显著降低相关(率比0.16;95%CI 0.09–0.26;p<0.001)。
- 全量术后比伐卢定较未输注或肝素组在各ACS类型中与结局改善一致相关。
关键数值与推荐
- 全量术后比伐卢定方案:1.75 mg/kg/h,持续≤4 h。
- 低剂量术后比伐卢定方案:0.25 mg/kg/h,持续≤6 h。
- 全量较低剂量主要终点率比0.21(95%CI 0.12–0.35;p<0.001,多因素校正)与0.16(95%CI 0.09–0.26;p<0.001,倾向评分校正)。
临床怎么用
- ACS患者PCI术后是否常规输注比伐卢定需个体化权衡,因输注与否主要终点无差异。
- 若选择术后输注,全量方案较低剂量方案与主要终点降低相关,但需结合出血风险判断。
- 全量术后比伐卢定在STEMI与NSTE-ACS中与未输注或肝素相比结局改善一致,可作为临床决策参考。
局限性
- 术后输注方案非随机分配,全量与低剂量比较由术者决定,存在选择偏倚可能。
- 全量组与低剂量组样本量及STEMI/NSTE-ACS构成不同,比较需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The value of prolonged bivalirudin infusion after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with or without ST-segment elevation remains unclear. OBJECTIVES: The purpose of this study was to assess efficacy and safety of a full or low post-PCI bivalirudin regimen in ACS patients with or without ST-segment elevation. METHODS: The MATRIX program assigned bivalirudin to patients without or with a post-PCI infusion at either a full (1.75 mg/kg/h for ≤4 h) or reduced (0.25 mg/kg/h for ≤6 h) regimen at the operator's discretion. The primary endpoint was the 30-day composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (composite of all-cause death, myocardial infarction, or stroke, or major bleeding). RESULTS: Among 3,610 patients assigned to bivalirudin, 1,799 were randomized to receive and 1,811 not to receive a post-PCI bivalirudin infusion. Post-PCI full bivalirudin was administered in 612 (ST-segment elevation myocardial infarction [STEMI], n = 399; non-ST-segment elevation acute coronary syndromes [NSTE-ACS], n = 213), whereas the low-dose regimen was administered in 1,068 (STEMI, n = 519; NSTE-ACS, n = 549) patients. The primary outcome did not differ in STEMI or NSTE-ACS patients who received or did not receive post-PCI bivalirudin. However, full compared with low bivalirudin regimen remained associated with a significant reduction of the primary endpoint after multivariable (rate ratio: 0.21; 95% CI: 0.12 to 0.35; p < 0.001) or propensity score (rate ratio: 0.16; 95% CI: 0.09 to 0.26; p < 0.001) adjustment. Full post-PCI bivalirudin was associated with improved outcomes consistently across ACS types compared with the no post-PCI infusion or heparin groups. CONCLUSIONS: In ACS patients with or without ST-segment elevation, the primary endpoint did not differ with or without post-PCI bivalirudin infusion but a post-PCI full dose was associated with improved outcomes when compared with no or low-dose post-PCI infusion or heparin (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX [MATRIX]; NCT01433627).
引用
- Gargiulo G, Carrara G, Frigoli E, et al. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2019. PMID: 30784669. doi:10.1016/j.jacc.2018.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。